scPharmaceuticals (SCPH)
(Delayed Data from NSDQ)
$5.09 USD
+0.05 (0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.09 USD
+0.05 (0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $5.09 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Zacks News
Does scPharmaceuticals (SCPH) Have the Potential to Rally 291.9% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for scPharmaceuticals (SCPH) points to a 291.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 0% and 0.17%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Biorestorative Therapies, Inc. (BRTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of 10.71% and 196.67%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Kiniksa Pharmaceuticals (KNSA) delivered earnings and revenue surprises of 33.33% and 23.68%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
scPharmaceuticals (SCPH) delivered earnings and revenue surprises of 20% and 6.17%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MaxCyte (MXCT) delivered earnings and revenue surprises of 35.71% and 46.35%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
SpringWorks Therapeutics (SWTX) delivered earnings and revenue surprises of -0.85% and 76.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 2.70% and 5.68%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
scPharmaceuticals, Inc. (SCPH) Loses -21.78% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for scPharmaceuticals, Inc. (SCPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) delivered earnings and revenue surprises of 16.67% and 20.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Recent Price Trend in scPharmaceuticals, Inc. (SCPH) is Your Friend, Here's Why
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
scPharmaceuticals, Inc. (SCPH) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
What Makes scPharmaceuticals, Inc. (SCPH) a New Buy Stock
by Zacks Equity Research
scPharmaceuticals, Inc. (SCPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 164% Upside in scPharmaceuticals, Inc. (SCPH): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 163.7% in scPharmaceuticals, Inc. (SCPH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Has scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how scPharmaceuticals, Inc. (SCPH) and Syndax Pharmaceuticals (SNDX) have performed compared to their sector so far this year.
scPharmaceuticals (SCPH) Plunges Despite Furoscix's FDA Approval
by Zacks Equity Research
scPharmaceuticals (SCPH) receives FDA approval for its proprietary heart failure therapy. It also reported a debt refinancing agreement to help with the drug launch.
scPharmaceuticals (SCPH) Plunges on Complete Response Letter
by Zacks Equity Research
scPharmaceuticals (SCPH) receives complete response letter from the FDA regarding an NDA for its pipeline candidate, Furoscix, as a potential treatment for congestion due to fluid overload in adult patients.
scPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
scPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
scPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
Hanger (HNGR) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Hanger (HNGR) Q3 performance is likely to have benefited from strong demand for Orthotic and Prosthetic services across the board.